Skip to main content
SRPT logo

Sarepta Therapeutics, Inc.

SRPTNASDAQHealthcareBiotechnology

$18.89Today:- (-)1Y −16.95%

As of Oct 27, 2026 close

Market cap
$1.99B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$14.68$24.68
Volume (live)
-
Avg. volume (3M)
2.89M

Sarepta Therapeutics (SRPT) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Sarepta Therapeutics used $205.48M of cash in operating activities and spent $109.85M on capital expenditures. That left free cash flow of −$315.33M. It repurchased $25.01M of its own shares.

Sarepta Therapeutics Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Sarepta Therapeutics, Inc. (SRPT) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-0.710.24-0.54-0.70-0.42-0.55-0.72-0.36-0.05
Depreciation & Amortization0.040.020.040.040.040.030.020.010.01
Deferred Income Tax0.000.000.000.000.020.010.000.000.00
Stock Based Compensation0.120.180.180.230.110.110.080.050.03
Change in Working Capital0.08-0.72-0.48-0.04-0.100.55-0.07-0.11-0.10
Change in Accounts Receivable0.20-0.20-0.19-0.06-0.05-0.01-0.04-0.02-0.02
Change in Inventory-0.30-0.40-0.15-0.05-0.08-0.06-0.05-0.04-0.07
Change in Accounts Payable0.100.11-0.050.150.020.040.120.090.01
Change in Other Working Capital0.07-0.20-0.100.02-0.090.58-0.10-0.14-0.02
Other Operating Activities0.070.18-0.100.15-0.09-0.040.220.02-0.12
Net Cash from Operating Activities-0.21-0.21-0.50-0.33-0.440.11-0.46-0.39-0.23
Investing Activities
Capital Expenditures-0.11-0.14-0.09-0.03-0.04-0.08-0.06-0.06-0.02
Acquisitions0.000.000.000.000.000.00-0.170.00-0.01
Purchases of Investments-0.29-1.10-2.05-1.94-0.03-1.33-1.19-1.17-0.59
Sales/Maturities of Investments0.302.181.870.920.471.191.720.870.31
Other Investing Activities-0.25-0.010.090.000.100.100.000.000.13
Net Cash from Investing Activities0.070.76-0.17-1.050.50-0.120.29-0.37-0.18
Financing Activities
Debt Repayment-0.160.000.00-0.800.000.290.25-0.030.58
Common Stock Issued0.020.080.000.030.550.310.370.510.35
Common Stock Repurchased-0.030.000.000.00-0.010.000.000.000.00
Other Financing Activities-0.020.05-0.01-0.10-0.010.080.030.56-0.05
Net Cash from Financing Activities-0.170.120.130.230.560.680.640.530.89
Summary
Net Change in Cash-0.300.67-0.54-1.140.610.670.47-0.230.48
Cash at Beginning of Period1.120.440.992.131.510.840.370.600.12
Cash at End of Period0.811.120.440.992.131.510.840.370.60
Free Cash Flow-0.32-0.34-0.59-0.36-0.480.03-0.52-0.45-0.25
Supplemental Disclosures
Interest Paid-0.020.020.040.060.03---
Income Taxes Paid-0.020.020.000.000.00---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Sarepta Therapeutics Cash Flow

What is Sarepta Therapeutics's free cash flow?

Sarepta Therapeutics had negative free cash flow of $315.33M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$205.48M minus $109.85M of capital expenditures.

How much does Sarepta Therapeutics spend on capital expenditures?

Sarepta Therapeutics spent $109.85M on capital expenditures in fiscal 2025, compared with $136.96M a year earlier.

Does Sarepta Therapeutics pay dividends or buy back shares?

Yes. In fiscal 2025 Sarepta Therapeutics returned $25.01M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition